Sanofi unit defends booster vaccine trademark in Europe

An EUIPO appeals board sided with the French pharma company’s vaccine division in a dispute with an India-based biotech company over Sanofi’s ‘Covaxis’ mark.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

The flaw that landed Sanofi a win in the rare disease space

4 September 2025 The company’s EPO victory over a rare disease biomarker patent highlights how precise claims and attention to objections can make or break biotech cases, reports Marisa Woutersen.

Europe

Sanofi successfully challenges rare disease patent in Europe

1 July 2025 French biopharma giant overturns German rival’s patent at the European Patent Office | Revocation based on insufficient disclosure of antibody production | Appeal focused on detection method claims and biomarker specificity.

Americas

Sanofi unit loses genetic disorder patent at EPO after trio of challenges

20 May 2025 Boards of Appeal revokes Genzyme patent, handing win to Accord Healthcare | Teva and Hetero Labs also previously filed oppositions | Patent refers to Cerdelga, part of Sanofi’s Gaucher disease franchise.

More features

Perkins Coie and Ashurst to merge into $2.7bn revenue firm

Pillsbury bags first-chair litigator and inventor with ‘business acumen’

Masimo bags $634m win over Apple—with latest watch under scrutiny

Too busy to save time? Why IP teams can’t afford to wait on AI

AZ counsel warns: EU Bolar exemption is ‘painful’ for pharma innovators

Novartis moves to quash SCOTUS review of Entresto case

Pfizer beats Novo Nordisk in $10bn bidding war

‘I need them and they need me’: Regeneron counsel on what makes a strong law firm partnership

Sanofi unit defends booster vaccine trademark in Europe

More on this story

Editor's picks

Editor's picks

More features